Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

(2020) Rémy Nicolle et al.   EBioMedicine

Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer

(2020) Lung-Hung Tsai et al.   Scientific Reports

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

(2019) Margaret A. Tempero et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma

(2019) Didier Dréau et al.   Frontiers in Oncology

Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer

(2019) Naim U. Rashid et al.   CLINICAL CANCER RESEARCH

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overexpression of MUC1 predicts poor prognosis in patients with breast cancer

(2018) Xuan Jing et al.   ONCOLOGY REPORTS

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

(2017) John P Neoptolemos et al.   LANCET

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

(2016) Katsuhiko Uesaka et al.   LANCET

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

(2015) Richard A Moffitt et al.   NATURE GENETICS

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

(2013) B. V. Sinn et al.   ANNALS OF ONCOLOGY

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

(2013) Helmut Oettle et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas

(2013) Sung-Im Do et al.   Journal of Breast Cancer

Mucins in pancreatic cancer and its microenvironment

(2013) Sukhwinder Kaur et al.   Nature Reviews Gastroenterology & Hepatology

MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes

(2013) S Nath et al.   Oncogenesis

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

(2012) Jan Budczies et al.   PLoS One

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas

(2010) Xiao-Na Fan et al.   PATHOLOGY RESEARCH AND PRACTICE